Your browser doesn't support javascript.
loading
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Serna-Blasco, R; Sánchez-Herrero, E; Sanz-Moreno, S; Rodriguez-Festa, A; García-Veros, E; Casarrubios, M; Sierra-Rodero, B; Laza-Briviesca, R; Cruz-Bermúdez, A; Mielgo-Rubio, X; Sánchez-Hernández, A; Uribelarrea, E A; Calvo, V; Romero, A; Provencio, M.
Afiliação
  • Serna-Blasco R; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
  • Sánchez-Herrero E; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain; Atrys Health, Barcelona, Spain.
  • Sanz-Moreno S; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
  • Rodriguez-Festa A; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
  • García-Veros E; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
  • Casarrubios M; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
  • Sierra-Rodero B; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
  • Laza-Briviesca R; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
  • Cruz-Bermúdez A; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
  • Mielgo-Rubio X; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
  • Sánchez-Hernández A; Medical Oncology Department, Hospital Provincial Centre de Castelló, Castellón de la Plana, Castellón, Spain.
  • Uribelarrea EA; Medical Oncology Department, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain.
  • Calvo V; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
  • Romero A; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. Electronic address: atocha10@hotmail.com.
  • Provencio M; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. Electronic address: mprovenciop@gmail.com.
ESMO Open ; 6(5): 100279, 2021 10.
Article em En | MEDLINE | ID: mdl-34607284
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article